Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins
December 05, 2016 07:00 ET
|
Akari Therapeutics, Plc
-Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing--PAS-Coversin pre-clinical data supports once weekly dosing--Phase II PNH patients identified with data expected...
Akari Therapeutics to Attend Upcoming Investor Conferences In November
November 11, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 08:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been...
Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
September 12, 2016 07:15 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and...
Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
April 14, 2016 07:30 ET
|
Akari Therapeutics Plc
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a...
Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin
March 31, 2016 16:03 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 31, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from...